History
  • No items yet
midpage
Public Patent Foundation, Inc. v. Glaxosmithkline Consumer Healthcare, L.P.
2011 U.S. Dist. LEXIS 88721
| S.D.N.Y. | 2011
Read the full case

Background

  • Plaintiff Public Patent Foundation filed a qui tam action in June 2009 alleging GlaxoSmithKline marked Citrucel products with expired patent numbers in violation of 35 U.S.C. § 292.
  • Patents at issue were Nos. 4,626,287 and 4,671,823, which expired on January 29, 2005; markings continued through 2009 before removal.
  • GSK began removing expired patent markings in fall 2009 and later adopted a process to identify patent expiration dates for labeling decisions.
  • Trial proceeded as a bench trial on June 6, 2011; Garrod’s proposed expert testimony was excluded; four GSK witnesses testified credibly about practices and knowledge.
  • Defendant moved for judgment as a matter of law under Rule 52(c) arguing Plaintiff failed to prove knowledge of falsity; the court granted the motion, ruling no intent to deceive was shown.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether plaintiff proved knowledge of falsity under § 292 Plaintiff asserts GSK knew markings were false or acted with intent to deceive. GSK lacked knowledge of expiration and lacked intent to deceive; no evidence of deception. Rule 52(c) motion granted; no knowledge shown.
Whether the evidence supports intent to deceive even if knowledge were proven If knowledge existed, intent to deceive is shown by conduct and purpose. No credible evidence of intentional deception; actions were not aimed at deceiving the public. Even assuming knowledge, record shows no conscious desire to deceive.
Effect of Solo Cup decision on the case Solo Cup clarified that marking expired patents can be deceptive; supports knowledge and intent. Solo Cup did not retroactively impose knowledge of falsity; evidence did not show deception. Later Solo Cup framework applied to assess knowledge, but still found no proof of deception.

Key Cases Cited

  • Clontech Labs., Inc. v. Invitrogen Corp., 406 F.3d 1347 (Fed. Cir. 2005) (knowledge of falsity required for § 292 false marking; strict intent standard)
  • Solo Cup Co. v. Pequignot, 608 F.3d 1356 (Fed. Cir. 2010) (expired-patent marks are false marking; presumption of intent with knowledge of falsity)
  • In re BP Lubricants USA Inc., 637 F.3d 1307 (Fed. Cir. 2011) (provides specific guidance on § 292 knowledge standards in false marking)
Read the full case

Case Details

Case Name: Public Patent Foundation, Inc. v. Glaxosmithkline Consumer Healthcare, L.P.
Court Name: District Court, S.D. New York
Date Published: Aug 10, 2011
Citation: 2011 U.S. Dist. LEXIS 88721
Docket Number: 09 Civ. 5881(RMB)
Court Abbreviation: S.D.N.Y.